Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1067-1074, 2007. First published April 26, 2007; 10.1373/clinchem.2006.080721
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 080721.Supplemental data
Right arrow All Versions of this Article:
clinchem.2006.080721v1
53/6/1067    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopez, M. F.
Right arrow Articles by Fishman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez, M. F.
Right arrow Articles by Fishman, D.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1067-1074.)
© 2007 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples

Mary F. Lopez1,a, Alvydas Mikulskis1, Scott Kuzdzal1, Eva Golenko1, Emanuel F. Petricoin, III2, Lance A. Liotta2, Wayne F. Patton1, Gordon R. Whiteley3, Kevin Rosenblatt4, Prem Gurnani4, Animesh Nandi4, Samuel Neill5, Stuart Cullen5, Martin O’Gorman5, David Sarracino6, Christopher Lynch1, Andrew Johnson1, William Mckenzie1 and David Fishman6

1 PerkinElmer Life and Analytical Sciences, Wellesley, MA.
2 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA.
3 Clinical Proteomics Reference Laboratory, Gaithersburg, MD.
4 Department of Pathology, Division of Translational Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
5 Nonlinear Dynamics, Cuthbert House, All Saints, Newcastle upon Tyne, United Kingdom.
6 Harvard Partners, Cambridge, MA.
7 New York University Medical School, Division of Obstetrics and Gynecology, New York, NY.

aAddress correspondence to this author at: PerkinElmer Life and Analytical Sciences, 45 Williams St., Wellesley, MA 02481-4008. Fax 617-574-9864; e-mail mary.lopez{at}perkinelmer.com.

Background: Most cases of ovarian cancer are detected at later stages when the 5-year survival is ~15%, but 5-year survival approaches 90% when the cancer is detected early (stage I). To use mass spectrometry (MS) of serum proteins for early detection, a seamless workflow is needed that provides an opportunity for rapid profiling along with direct identification of the underpinning ions.

Methods: We used carrier protein–bound affinity enrichment of serum samples directly coupled with MALDI orthagonal TOF MS profiling to rapidly search for potential ion signatures that contained discriminatory power. These ions were subsequently directly subjected to tandem MS for sequence identification.

Results: We discovered several biomarker panels that enabled differentiation of stage I ovarian cancer from unaffected (age-matched) patients with no evidence of ovarian cancer, with positive results in >93% of samples from patients with disease-negative results and in 97% of disease-free controls. The carrier protein–based approach identified additional protein fragments, many from low-abundance proteins or proteins not previously seen in serum.

Conclusions: This workflow system using a highly reproducible, high-resolution MALDI-TOF platform enables rapid enrichment and profiling of large numbers of clinical samples for discovery of ion signatures and integration of direct sequencing and identification of the ions without need for additional offline, time-consuming purification strategies.




The following articles in journals at HighWire Press have cited this article:


Home page
 J Ultrasound MedHome page
A. C. Fleischer, A. Lyshchik, H. W. Jones III, M. A. Crispens, R. F. Andreotti, P. K. Williams, and D. A. Fishman
Diagnostic Parameters to Differentiate Benign From Malignant Ovarian Masses With Contrast-Enhanced Transvaginal Sonography
J. Ultrasound Med., October 1, 2009; 28(10): 1273 - 1280.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. G. Miller, D. E. Bruns, G. L. Hortin, S. Sandberg, K. M. Aakre, M. J. McQueen, Y. Itoh, J. C. Lieske, D. W. Seccombe, G. Jones, et al.
Current Issues in Measurement and Reporting of Urinary Albumin Excretion
Clin. Chem., January 1, 2009; 55(1): 24 - 38.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. A. Liotta and E. F. Petricoin
Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and away from the Measurement Platform
Clin. Chem., January 1, 2008; 54(1): 3 - 5.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. P. Diamandis
Oncopeptidomics: A Useful Approach for Cancer Diagnosis?
Clin. Chem., June 1, 2007; 53(6): 1004 - 1006.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.